Status:
UNKNOWN
Flow Mediated Dilation in Association With Hyperuricemia
Lead Sponsor:
Assiut University
Conditions:
SLE
Cardiovascular Diseases
Eligibility:
FEMALE
18-45 years
Brief Summary
Assess cardiovascular affection and subclinical atherosclerosis in patients with systemic lupus using the non invasive flow mediated dilation. evaluate the role of uric acid as independent marker of ...
Detailed Description
Systemic lupus erythematosus (SLE) is a complex autoimmune disease that is characterized by multiple end-organ damage and predominantly affects premenopausal women. Cardiovascular disease is a major ...
Eligibility Criteria
Inclusion
- female patient with SLE aged more than 18
Exclusion
- male patients
- patient with established cardiovascular disease, patients with end stage renal disease
Key Trial Info
Start Date :
July 30 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 27 2023
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT05342285
Start Date
July 30 2022
End Date
December 27 2023
Last Update
July 20 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assuit University
Asyut, Egypt